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Available online 25 October 2019We report a 15-year-old female with POLG-related mitochondrial disease who developed severe multifocal
epilepsia partialis continua, unresponsive to standard anti seizure drug treatment and general anesthesia.
Based on an earlier case report, we treated her focal seizures that affected her right upper limb with 20-min ses-
sions of transcranial direct current stimulation (tDCS) at an intensity of 2mAon each offive consecutive days. The
cathode was placed over the left primary motor cortex, the anode over the contralateral orbitofrontal cortex.
Surface electromyography (EMG) were recorded 20 min before, 20 min during, and 20 min after four of five
tDCS sessions to measure its effect on the muscle jerks. The electroencephalography (EEG) was recorded before
and after tDCS to measure the frequency of spikes. Our results showed no statistically or clinically significant
reduction of seizures or epileptiformactivity using EEG and EMG,with this treatment protocol. To our knowledge,
this is only the second time that adjunct tDCS treatment of epileptic seizures has been tried in POLG-related mi-
tochondrial disease. Taken togetherwith thepositivefindings from the earlier case report, the present studyhigh-
lights that more data are needed to determine if, and under which parameters, the treatment is effective.






Refractory status epilepticus1. Introduction
Mitochondrial diseases are a group of genetic disorders affecting
about one in 5000 people [1]. The symptoms are diverse but since
mitochondria produce energy for body tissues through production of
adenosine triphosphate (ATP), organs with high energy consumption,
such as the brain, are often affected. For example, as many as 35% to
60% of people with mitochondrial disease develop seizures [1]. In
POLG-related mitochondrial disease, a genetic mutation interferes
with a catalytic subunit of the mitochondrial DNA polymerase gamma,
which replicates mitochondrial DNA [2], leading to depleted mitochon-
drial DNA [3]. Once the resulting neuronal energy failure reaches a







. This is an open access article underacts as the trigger for epilepsy that in turn increases neuronal loss [4].
A study found mitochondrial dysfunction in one third of patients with
epilepsy that underwent metabolic testing [5], emphasizing that drug-
resistant seizures are a frequent problem in mitochondrial disease,
and that new treatments need to be developed. In a previous case re-
port, focal seizures in a patientwith POLG-relatedmitochondrial disease
ceased after twoweeks of transcranial direct current stimulation (tDCS)
[6]. Since these seizures are often refractory to medical treatment and
the technique is non-invasive, we tested tDCS using similar parameters
as in Ng et al. [6] in a patient with POLG-related mitochondrial disease
and drug-resistant multifocal epilepsy.
1.1. Case report
This 15-year-old female was apparently healthy until the first
admission followed two consecutive generalized tonic–clonic seizures.
Prior to the seizures, she had experienced nausea, headache, reduced
vision and paraesthesia in both upper limbs. She was intubated during
helicopter transfer to hospital due to reduced consciousness. Following
admission, she regained consciousness, but developed continuous
jerking of her right arm. EEG showed ongoing epileptiform discharges
over the right occipital region (Fig. 1A) that later involved most of thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. POLG disease visualized through EEG examples. Panel A) EEG sample from the patient from an early clinical recording, showing almost continuous 2 Hz polyspike-and-slowwaves
mainly over the right parieto-occipital region. Panel B) Continuous EEG recording from the tDCS experiment showing channels (from top to bottom) C4, C3, P3, O1 and EMG1 and EMG2
being the right hand and left trapezius, respectively.
2 L. Marquardt et al. / Epilepsy & Behavior Reports 12 (2019) 100339right cerebral hemisphere, and because of persisting uncontrolled epi-
leptic activity she was loaded with phosphenytoin before using anes-
thesia with propofol and ketamine at relevant clinical dosages to
provide effective serum levels, as well as lowering her core body tem-
perature to 33 °C in accordance with the Norwegian treatment guide-
lines [7]. The clinical presentation with status epilepticus involving an
occipital lobe focus prompted investigation for POLG mutation, whichwas subsequently confirmed through DNA sequencing analysis show-
ing a homozygous genotype c.2243GNC.
Following two episodes of propofol anesthesia and achieving burst
suppression, she regained consciousness and her epilepsy was then
treated with phenobarbital and oxcarbazepinewhile withdrawing phe-
nytoin. After stabilization, the patient was discharged with ongoing
medication treatment. She was readmitted a second and third time
3L. Marquardt et al. / Epilepsy & Behavior Reports 12 (2019) 100339with headache and visual disturbances that quickly morphed into gen-
eralized tonic–clonic seizures, followed by focal motor status epilepti-
cus, both episodes treated with anesthesia and hypothermia. On the
third occasion, her MRI showed new changes in both occipital regions.
During the second prolonged admission, she still had jerking of her
right armdespitemaintaining phenytoin, levetiracetam, oxcarbazepine,
topiramate and clobazam at therapeutic doses. At the point where tDCS
treatment was instituted, the patient had a multifocal seizures with
multiple semiologies (Fig. 1A and B) including a multifocal, asynchro-
nous myoclonus, that was dominant and most debilitating in the right
hand. We thus targeted the left primary motor cortex with tDCS, as
the myoclonus activity most likely arose from that area, with the goal
to relieve pain and disability.Fig. 2. tDCSmontage and results. Panel A) Placement of anode at Fp2 (red) and cathode at C3 (bl
all four days. Time in minutes. Panel C) Spikes/jerks per second and 95% confidence intervals b1.2. Methods of tDCS and EEG
The use of tDCS was discussed with the local ethical committee who
considered it a form of supplementary experimental treatment whose
purpose was to provide care for an individual, and for which the caring
physician could take responsibility without obtaining the committees'
approval. Verbal consent was obtained from the parents and treatment
was reported in the patient's medical journal. tDCS was applied for
20 min at 2 mA on each of five consecutive days with a DC-Stimulator
PLUS (neuroConn, Ilmenau, Germany) through 5 × 7 cm rubber elec-
trodes with saline soaked sponges giving a current density of
0.057 mA/cm2. The patient displayed continuous jerking in the right
hand muscles and left shoulder muscles. To reduce the jerking of theue)within the international 10/20 system. Panel B)Means of spikes/jerks per second across
efore, during, and after treatment.
4 L. Marquardt et al. / Epilepsy & Behavior Reports 12 (2019) 100339right hand, the cathode was placed over the contralateral left primary
motor cortex at approximately C3 of the 10–20 EEG system (see
Fig. 2A). The rationale was that cathodal stimulation has been shown
to reduce cortical excitability in the brain area underneath the electrode
and hencemight reduce epileptic activity causing themyoclonus [8]. The
anode was placed on the right orbitofrontal cortex (approximately Fp2).
By placing the electrode on the contralateral side, the electric field be-
tween anode and cathode crosses the midline and was hoped to affect
themotor cortexmost effectively. Since the anode is active and expected
to increase cortical excitability, a better setup would have included an
extra-large anode that would effectively reduce the current strength.
However, as the tDCS treatment was issued at short notice, we did not
have large electrodes available at the time.We chose the orbitofrontal re-
gion, because it is often used as a control site in tDCS experiments [9] and
because it was not particularly affected by epilepsy. Indeed, we did not
observe a worsening in the EEG in this region after the treatment. The
tDCS setup was used in accordance with safety guidelines [10,11].
Initial EEG recordings and seizuremonitoring during status epilepti-
cuswere donewith continuous 25 channel clinical EEG and scored visu-
ally by experienced neurophysiologists. With the cathode placed over
the left primary motor cortex, we looked for improvement particularly
in the right hand. Continuous EEG was measured from C3 and C4
(right motor cortex as control) for 20 min before and 20 min after
tDCS, from a clinical EEG setup following the 10/20 system with 6 + 2
(F3, F4, P3, P4, O1, O2) electrodes and video monitoring of the patient.
EMG data from the right hand and left trapezius was acquired continu-
ously for 20min before tDCS, during 20min tDCS, and20min after tDCS.
EEG data was not interpretable during tDCS due to amplifier blocking.
EMG and EEG data were recorded on four out of five days.
Three separate raters, two neurophysiologists (TE, HKO) and the
tDCS clinician (LM), counted the frequency of spikes (EEG) and muscle
jerks (EMG) drawn from multiple random samples. Specifically, the
datawere binned into 12 five-minute segments. Then, each rater picked
randomly ten, artifact-free one-second periods from each five-minute
segment on all four days and determined the mean number of EEG
spikes and EMG jerks per second (Hz) for all four measurements (C3,
C4, right hand, left trapezius). Subsequently, means were calculated
across raters (see Fig. 2B) and EEG data was subjected to paired sample
t-tests andnon-parametricWilcoxon tests, comparing spikes before and
after tDCS. The means for EMG data were subjected to an ANOVA with
the repeated measures variable Time (before, during after tDCS) and a
non-parametric Friedman test. Non-parametric Friedman andWilcoxon
tests were included because not all variables met the normal distribu-
tion criterion necessary for t-tests and ANOVAs — due to the limited
range of values for spikes/jerks per second. At the same time, non-
parametric tests are sometimes not sensitive enough to pick up small
effects. In the interest of comprehensiveness, we thus decided to report
findings from both ANOVA/Friedman and paired sample t-tests/
Wilcoxon tests. We also compared the pre-tDCS data on day one (base-
line) to the post-tDCS data on day five using t- and Wilcoxon tests,
assuming that the treatment effect should be strongest between these
measurement points.
2. Results
Fig. 2C shows the average frequency of epileptic spikes and jerks in
the right hand and left shoulder during treatment. According to t-
tests/Wilcoxon tests for EEG data and the ANOVAs/Friedman tests for
EMG data, there were no significant differences in the means across all
raters in C3 or C4 spikes (all ts(15) ≤ 0.613, all ps ≥ 0.549; all χ2s(1) ≤
0.091, all ps ≥ 0.763) as well as jerks in the right hand and left shoulder
(all Fs(2,30) ≤ 1.74, all ps ≥ 0.192; all Zs ≥ 0.642, all ps ≥ 0.521). The mean
spikes and jerks across all raters for pre-tDCS on day one (baseline) ver-
sus post-tDCS on day five were for the right hand 4.58 ± 0.32 and 4.42
±0.57, left trapezius 4.58±0.32 and4.08±0.42 jerks/s, C3 4.50±0.43
and 4.25 ± 0.32 and C4 4.25 ± 0.32 and 4.13 ± 0.17 spikes/s,respectively. None of these changes were significant (all ts ≤ 1.57, all
ps ≥ 0.215; all Zs ≤ 1.34, all ps ≥ 0.180).
TDCS treatmentwas given inMarch 2018. The stimulation itself was
well tolerated. The patient only reported short-term skin irritation from
the net holding the electrodes in place. Four months after receiving
tDCS, the patient was discharged from the hospital, still with upper
limb jerking, but was readmitted in December 2018 and died due to a
super-refractory status epilepticus.
3. Discussion
Neither spike nor jerk frequency changed over the course of five
tDCS sessions (between before, during, and after tDCS) or when com-
paring baseline spike/jerk rates from day one to after treatment on
day five. We therefore conclude that – in this case study – tDCS did
not have a beneficial treatment effect on treatment-resistant refractory
epilepsia partialis continua in POLG-related mitochondrial disease.
Hence, our results are inconsistent with those of Ng et al. [6], who
found that seizures stopped completely in a similar case study.
There are several differences between the two case studies that
could explain the different outcomes: Ng et al. [6] placed the cathode
over the right temporo-parietal–occipital junction (P4/T6), while in
our study it was over the left primary motor cortex. Ng et al. provided
tDCS treatment twice, once for three days and once for 14 days, while
we provided tDCS treatment once for five days. However, the treatment
in our case was stopped before the completion of 14 days because there
was no sign of improvement and due to technical reasons/staff avail-
ability. Moreover, while the patients appeared to have similar seizure
frequency their genotypes were different; the patient reported by Ng
and colleagues was homozygous for the c.1399GNA whereas our pa-
tient was homozygous for the c.2243GNC genotype. Both patients
were also on multiple, but different anticonvulsant regimens, raising
the possibility that competing mechanisms modulated response to
tDCS. Lastly, our casewas severe, so by the timewe started the interven-
tion the seizures may have become refractory to both medication and
tDCS treatment. We cannot rule out that cathodal stimulation else-
where (e.g., over the right occipital region) might have yielded a better
treatment response, perhaps, at an earlier stage of the disease. However,
while the patient had a multifocal epilepsy with multiple semiologies,
we specifically targeted the left motor cortex to reduce the myoclonic
jerking of the right hand that the patient found very debilitating. Simi-
larly, we cannot rule out that stimulating for more than five days
would have worked better.
According to guidelines published by a European expert consortium
in 2017, and several reviews, it is not yet possible to draw conclusions
regarding the efficacy of tDCS in any kind of epilepsy, even though
there are some promising results [12–15]. Similarly, it remains unclear
whether transcranial magnetic stimulation (TMS), another type of
non-invasive brain stimulation, is an effective treatment of epilepsy
[16–18], although there are some positive findings for epilepsia partialis
continua [19]. Even less is known about how these non-invasive brain
stimulation techniques will affect patients with mitochondrial diseases.
However, given that refractory epilepsy appears to be common in these
diseases [5], finding novel treatments is highly relevant. To our knowl-
edge, this is only the second documented attempt to use tDCS in mito-
chondrial disease. With one positive and one negative result, it is too
early to saywhether tDCSwillfinda place in the treatment ofmitochon-
drial epilepsy, but during the early stages of any new treatment, all find-
ings, negative or positive, need to be published to obtain a clearer
overall picture. This is particularly relevant in this case, where almost
nothing is known about the efficacy of tDCS for epilepsy in patients
with mitochondrial diseases. Further, because the condition is so rare,
it is difficult to realize randomized controlled trials with decent sample
sizes and that could control for potential placebo effects. A final reason
forwhywe deem it important to report this negative finding is – despite
its limited contribution to the literature – that there is growing
5L. Marquardt et al. / Epilepsy & Behavior Reports 12 (2019) 100339awareness of reporting bias and replication issues in the scientific com-
munity and with it a growing recognition of the relevance of negative
findings. We hope that our findings contribute to a growing body of lit-
erature and encourage other scientists to provide larger samples and
proper clinical trials.
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